CN106309616A - 一种具有降血脂效果的药物 - Google Patents
一种具有降血脂效果的药物 Download PDFInfo
- Publication number
- CN106309616A CN106309616A CN201610950085.9A CN201610950085A CN106309616A CN 106309616 A CN106309616 A CN 106309616A CN 201610950085 A CN201610950085 A CN 201610950085A CN 106309616 A CN106309616 A CN 106309616A
- Authority
- CN
- China
- Prior art keywords
- alcohol
- medicine
- water
- lipid
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title abstract description 6
- 230000000055 hyoplipidemic effect Effects 0.000 title description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000009835 boiling Methods 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims abstract description 4
- 239000002552 dosage form Substances 0.000 claims abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims 3
- 238000002156 mixing Methods 0.000 claims 2
- 241000628997 Flos Species 0.000 claims 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 240000000249 Morus alba Species 0.000 abstract description 15
- 235000008708 Morus alba Nutrition 0.000 abstract description 15
- 235000009008 Eriobotrya japonica Nutrition 0.000 abstract description 13
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract description 12
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract description 12
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract description 12
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract description 12
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract description 12
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract description 12
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract description 12
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract description 12
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract description 12
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract description 12
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 244000046146 Pueraria lobata Species 0.000 abstract description 9
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 244000061508 Eriobotrya japonica Species 0.000 abstract 1
- 241001092070 Eriobotrya Species 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 241001092040 Crataegus Species 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- 241000723353 Chrysanthemum Species 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种具有降血脂效果的药物，其特征在于由以下重量份的原料制备而成：枇杷:山楂:桑叶:菊花:葛根=1:1:1:1:1。其制备方法中包含以下步骤：1）按原料比例取原料粉碎混匀，用水煮后过滤再醇煮后过滤，合并两次的滤液；或按原料比例取原料粉碎混匀后，用醇煮后过滤再水煮后过滤的方先后提取后，合并两次的滤液；2）将滤液进行除醇、浓缩，再根据成品剂型添加或不添加药物辅料制成成品。实验证实：该药物具有降血脂的效果。
Description
技术领域
本发明涉及生物医药技术领域，特别涉及一种具有降血脂效果的药物。
背景技术
高血脂症是一种常见的疾病，系人体脂代谢失常所致，主要指血清中总胆固醇、甘油三酯和低密度脂蛋白水平过高或高密度脂蛋白水平过低。高血脂症早期没有明显的临床症状，它对身体的损害是隐匿性、渐行性的，而且是全身性的。因为高血脂可加速动脉粥样硬化，一旦动脉堵塞，就会引起很多疾病，如心脑血管疾病、肾脏病、肝脏疾病等。心脑血管疾病是中老年人致死的主要原因，是威胁人类健康的头号杀手。据世界卫生组织统计，每年大约有1700万人死于这种慢性疾病，占全球总死亡人数的30%左右。换言之，平均每3个死者中，就有1个是由心血管疾病引起的。
现在用于降脂的治疗药物很多，但在临床中，没有突出疗效的药物，因此市场急需开发一种治疗高血脂症状药物。
枇杷，中文古名为芦橘，又名金丸或芦枝，其是蔷薇科中的苹果亚科的一个属，为常绿小乔木。目前研究显示枇杷叶具有降低体脂肪、抗发炎、抗肿瘤、降血糖及改善异常代谢的疗效。
山楂是天然的降脂药，主要含有山楂酸、柠檬酸、脂肪分解酸、维生素C、黄酮、碳水化合物等成分，具有扩张血管、改善微循环、降低血压、促进胆固醇排泄而降低血脂的防病养生作用。
桑叶为桑科植物桑的干燥叶 ,自古以来中医就将桑叶作为治疗消渴症的中药应用于临床。近年来对桑叶的研究报道很多, 其中桑叶多糖和多肽都有很好的降糖及降血脂的作用 。
菊花,在植物分类学中是菊科、菊属的多年生宿根草本植物。用于风热感冒，头痛眩晕，目赤肿痛搜索，眼目昏花。
葛根具有改善脑部血液循环之效，对因高血压引起的头痛、眩晕、耳鸣及腰酸腿痛等症状有较好的缓解功效。
发明内容
本发明源于中医理论，总结多方经验，研制成了一种具有降血脂效果的药物，该药物为纯中药制剂，实验证明可大大降低血液中总胆固醇、甘油三酯、低密度脂蛋白和高密度脂蛋白，而且疗效确切，安全有效。
本发明目的在于提供一种具有降血脂效果的药物，以提供一种安全有效的药物选择，在降血脂治疗方面应用在临床上。
一种具有降血脂效果的药物，其特征在于由以下重量份的原料制备而成：
枇杷:山楂:桑叶:菊花:葛根=1:1:1:1:1。
具有降血脂效果的药物，其特征在于制备方法中包含以下步骤：
1）按原料比例取原料粉碎混匀，用水煮后过滤再醇煮后过滤，合并两次的滤液；
或按原料比例取原料粉碎混匀后， 用醇煮后过滤再水煮后过滤的方先后提取后，合并两次的滤液；所述的醇为70%-100%体积比的乙醇水溶液。
2）将滤液进行除醇、浓缩，再根据成品剂型添加或不添加药物辅料制成成品。
于所述的醇为70%-100%的乙醇水溶液。
具体实施方式
为了使本发明所述的内容更加便于理解，下面结合具体实施方式对本发明所述的技术方案做进一步的说明，但是本发明不仅限于此。
实施例1
药物组合物提取
取枇杷10g、山楂10g、桑叶10g、菊花10g、葛根10g，粉碎混匀，用1000 mL(1：20料液比)70%酒精渗漉1h，之后在90℃油浴回流提取2h，静置12h,滤过出去残渣。
取枇杷10g、山楂10g、桑叶10g、菊花10g、葛根10g，粉碎混匀，用1500 mL(1：30料液比)水渗漉1h，之后在100℃油浴回流提取2h，静置12h, 滤过出去残渣。
然后将两次提取物滤液合并，旋蒸除去乙醇并浓缩至合适浓度。
按照上述方法，分别提取枇杷、山楂和桑叶。
动物实验
将20-30g的昆明小鼠随机分为正常组、对照组、枇杷组、山楂组、桑叶组、高剂量组、中剂量组、低剂量组、辛伐他汀组，每组5只，每天自由饮食高脂饲料，以每次200ul剂量每日给药一次，连续给药2周。眼球取血，用总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL-C）、低密度脂蛋白（LDL-C）试剂盒检测各值，在酶标仪510 nm处检测总胆固醇和甘油三酯的吸光值，在546 nm处检测高密度脂蛋白和低密度脂蛋白吸光值，按照试剂盒的公式算出小鼠总胆固醇、甘油三酯、高密度脂蛋白和低密度脂蛋白的值，结果如表1所示。
图表1所示，枇杷组、山楂组和桑叶组组间各项指标没有显著性差异，和高脂模型组各指标相比，相对有较小幅度的升高；然而组合物高剂量组相对中剂量组、低剂量组和辛伐他汀组，能够显著地降低总胆固醇、甘油三酯和低密度脂蛋白含量，升高高密度脂蛋白含量。综上，组合物高剂量能够有效降脂作用。
实施例 2
饮料
枇杷10g、山楂10g、桑叶10g、菊花10g、葛根10g，粉碎后混合均匀，采用水煮法(1：20料液比)提取，后将滤渣用70%乙醇水溶液（1：30料液比)回流提取后过滤，合并提取液，浓缩至适量，提取稠膏，减压干燥，粉碎，得干浸膏粉。
取上述干浸膏粉，按常规工艺程序，即包含调配 - 均质 - 脱气 - 巴氏杀菌 -灌 装 - 冷却等步骤，即可得到成品饮料。
实施例3
合剂
取枇杷10g、山楂10g、桑叶10g、菊花10g、葛根10g各两份粉碎后混合均匀，分别采用水煎煮法(1：15料液比)和乙醇溶液（95%）（1：20料液比)煮法合并提取液，过滤后减压回收乙醇至无乙醇味，冷藏24h，吸取上清液，加入苯甲酸钠0.3%，尼泊金乙酯0.02%，煮沸半个小时，用蒸馏水调节至总量，冷却，滤过，灭菌即得。
实施例4
胶囊剂
取枇杷10g、山楂10g、桑叶10g、菊花10g、葛根10g各两份粉碎后混合均匀平均分为两份，分别采用水煎煮法(1：18料液比)和乙醇溶液（85%）（1：25料液比)煮法合并提取液，浓缩至适量，提取稠膏，减压干燥，粉碎，得干浸膏粉。
取上述干浸膏粉，按照常规工艺加入滑石粉、淀粉，混合均匀，制粒，装胶囊，即得胶囊。
实施例5
片剂
取枇杷10g、山楂10g、桑叶10g、菊花10g、葛根10g各两份粉碎后混合均匀,采用乙醇溶液（80%）煮(1：27料液比)提取，后将滤渣用水煮（1：20料液比)提取后过滤，之后合并滤液，浓缩至适量，喷雾干燥，干膏粉加辅料适量，混匀，过60目筛，压片，包衣，即得。
Claims (3)
1.一种具有降血脂效果的药物，其特征在于由以下重量份的原料制备而成：
枇杷:山楂:桑叶:菊花:葛根=1:1:1:1:1。
2.如权利要求1所述的具有降血脂效果的药物，其特征在于制备方法中包含以下步骤：
1）按原料比例取原料粉碎混匀，平均分为两份，一份用水煮后后过滤，另一份醇煮后过滤，合并两次的滤液；
或是按原料比例取原料粉碎混匀原料粉碎混匀后，用醇煮后过滤再水煮后过滤或水煮后过滤再醇煮后过滤的方法先后提取后，合并两次的滤液；
2）将滤液进行除醇、浓缩，再根据成品剂型添加或不添加药学上可接受的药物辅料制成成品。
3.如权利要求2所述的具有降血脂效果的药物，其特征在于所述的醇为70%-100%体积比的乙醇水溶液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610950085.9A CN106309616A (zh) | 2016-11-03 | 2016-11-03 | 一种具有降血脂效果的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610950085.9A CN106309616A (zh) | 2016-11-03 | 2016-11-03 | 一种具有降血脂效果的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106309616A true CN106309616A (zh) | 2017-01-11 |
Family
ID=57818747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610950085.9A Pending CN106309616A (zh) | 2016-11-03 | 2016-11-03 | 一种具有降血脂效果的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309616A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110771761A (zh) * | 2019-11-06 | 2020-02-11 | 合肥工业大学 | 一种具有辅助降血脂功效的葛根皇菊复合饮料 |
-
2016
- 2016-11-03 CN CN201610950085.9A patent/CN106309616A/zh active Pending
Non-Patent Citations (3)
| Title |
|---|
| WONDER_2012X: "妙用山楂可降脂", 《HTTPS://WENKU.BAIDU.COM/VIEW/E4F354E7D15ABE23482F4DB7.HTML》 * |
| 刘庆春: "《糖尿病就这样吃》", 31 March 2013, 中华工商联合出版社 * |
| 陈冰等: "《肥胖症药膳》", 28 February 2003, 科学技术文献出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110771761A (zh) * | 2019-11-06 | 2020-02-11 | 合肥工业大学 | 一种具有辅助降血脂功效的葛根皇菊复合饮料 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (zh) | 一种具有降血糖降血脂作用的组合物 | |
| CN104435749B (zh) | 一种铁皮石斛复方制剂及其制备方法和应用 | |
| CN101239112A (zh) | 调节血脂的中药组合物及其制备方法 | |
| CN103070880B (zh) | 白簕多糖在制备治疗糖尿病药物中的应用 | |
| WO2014094632A1 (zh) | 一种治疗头痛的药物组合物及其制备方法 | |
| CN103127232A (zh) | 桑叶方总提物及其制剂和用途 | |
| CN103705594B (zh) | 治疗高脂血症的中药组合物及其制备方法 | |
| CN104173451B (zh) | 一种天然药物组合物在降血糖药品及保健食品中的应用 | |
| CN102973719A (zh) | 一种具有润肠通便功能的中药保健食品及制备方法 | |
| CN102319289B (zh) | 肉桂多酚等组成的降血糖中药组合物及其制备方法 | |
| CN100571740C (zh) | 一种降血糖、降血脂的中药组合物及制法和应用 | |
| CN106376820A (zh) | 一种用于驱胃寒、保护胃黏膜的固体饮料及其制备方法 | |
| CN102846879B (zh) | 一种降血脂的组合物 | |
| CN104474472A (zh) | 具有降三高作用的苦丁茶含片及其生产方法 | |
| CN103705578B (zh) | 具有降血脂与抑制血糖升高作用的中药制剂及其制备方法 | |
| CN103385931B (zh) | 一种降血糖的药物组合物 | |
| CN102283884A (zh) | 一种三七余甘子组合物及用途 | |
| CN106309616A (zh) | 一种具有降血脂效果的药物 | |
| CN100551396C (zh) | 一种治疗脂肪肝的中成药及其制备方法 | |
| CN104013696B (zh) | 一种防治代谢综合征的植物药组合物及其应用 | |
| CN102670672A (zh) | 苦丁茶提取物在制备降低肝脏甘油三酯含量的药物中的用途 | |
| CN103505664A (zh) | 一种含有决明子的降血脂组合物及制备方法 | |
| CN1115159C (zh) | 一种含紫丹参的药物组合物及其制备方法和应用 | |
| CN104906243A (zh) | 一种护肝的中药组合物 | |
| CN105477465A (zh) | 一种具有保护肝功能的中药制剂及其制备工艺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |